Product Information
MK-0941 is a potential therapeutic for the treatment of type 2 diabetes. It is a novel, orally active, small molecule that has been shown to reduce blood glucose levels in preclinical models. MK-0941 targets pancreatic and hepatic steatosis by inhibiting the uptake of triglycerides from plasma into these tissues. MK-0941 also increases insulin sensitivity in vitro and in vivo. This drug has been studied as monotherapy at doses of 0.1, 1, or 10 mg/kg and as combination therapy with metformin at doses of 5 or 25 mg/kg in db/db mice and wild-type mice. The study drug was well tolerated up to 10 mg/kg without any adverse effects on body weight or food intake observed.
MK-0941 has shown promising results in lowering blood glucose levels and improving insulin sensitivity when administered alone or in combination with metformin at high doses.
Chemical properties
Technical inquiry about: 3D-MVB91697 MK-0941
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
